scholarly journals Secukinumab therapy in reactive arthritis: Report of two cases

2021 ◽  
Author(s):  
Prasanta Padhan ◽  
Debashis Maikap
Keyword(s):  
Reactive Arthritis ◽  
Tumour Necrosis ◽  
Treatment Options ◽  
Lower Limbs ◽  
Disease Modifying Antirheumatic Drugs ◽  
Antirheumatic Drugs ◽  
Immune Mediated ◽  
Factor Inhibitor ◽  
Inflammatory Drugs ◽  
Necrosis Factor

ABSTRACT Reactive arthritis (ReA) is an immune-mediated aseptic synovitis resulting either from genitourinary or gastrointestinal tract, commonly presenting as oligoarthritis of the lower limbs and rarely urethritis and conjunctivitis. The treatment options include nonsteroidal anti-inflammatory drugs, conventional disease-modifying antirheumatic drugs, and biologics in severe cases. We report successful use of secukinumab in two cases of chronic severe ReA who initially failed to treatment with tumour necrosis factor inhibitor.

scholarly journals MANAGEMENT OF RHEUMATOID ARTHRITIS: SPECIAL CONSIDERATION FOR BIOLOGIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS

2018 ◽  
Vol 11 (11) ◽  
pp. 47 ◽  
Author(s):  
Salmi Abdul Razak ◽  
Mohd Makmor-bakry ◽  
Adyani Md Redzuan
Keyword(s):  
Rheumatoid Arthritis ◽  
Tumor Necrosis ◽  
Tumor Necrosis Factor Inhibitor ◽  
Special Consideration ◽  
Biologic Therapies ◽  
Disease Modifying Antirheumatic Drugs ◽  
Antirheumatic Drugs ◽  
Factor Inhibitor ◽  
Disease Modifying ◽  
Necrosis Factor

Rheumatoid arthritis (RA) is a progressive chronic inflammatory disease affecting 0.5–1.0% of the adult population worldwide. Due to the damages caused by this autoimmune disease, new biologic therapies, particularly the biologic disease-modifying antirheumatic drugs (bDMARDs), are now being the treatment of choice in the management of RA. However, special precaution and prescreening before the usage of bDMARDs are needed to ensure better clinical response and avoiding risk of adverse event during treatment with the selected bDMARDs. In this review paper, we will provide overview on the incidence and pathogenesis of the disease, available pharmacological treatment and emphasizing special consideration in need on initiation of bDMARDs among RA patients. A literature review was performed by searching for relevant articles in Medline database through PubMed using medical subject headings terms and keywords: RA, bDMARDs, special consideration, tumor necrosis factor inhibitor, and non-tumor necrosis factor inhibitor. All papers reviewed were from 1999 to 2017 and were written in English. In this article, use of conventional synthetic DMARDs (csDMARDs), bDMARDs and special consideration to be taken upon initiation of biologic therapies in RA will be reviewed.

scholarly journals Evaluation of the efficacy and safety of sarilumab combination therapy in patients with rheumatoid arthritis with inadequate response to conventional disease-modifying antirheumatic drugs or tumour necrosis factor α inhibitors: systematic literature review and network meta-analyses

RMD Open ◽  
2019 ◽  
Vol 5 (1) ◽  
pp. e000798 ◽  
Author(s):  
Ernest Choy ◽  
Nick Freemantle ◽  
Clare Proudfoot ◽  
Chieh-I Chen ◽  
Laurence Pollissard ◽  
...  
Keyword(s):  
Tumour Necrosis ◽  
Efficacy And Safety ◽  
Tumour Necrosis Factor Α ◽  
Disease Modifying Antirheumatic Drugs ◽  
Antirheumatic Drugs ◽  
Serious Adverse Events ◽  
Serious Infections ◽  
Meta Analyses ◽  
Factor Α ◽  
Necrosis Factor

ObjectiveTo compare efficacy and safety of subcutaneous sarilumab 200 mg and 150 mg every 2 weeks plus conventional synthetic disease-modifying antirheumatic drugs (+csDMARDs) versus other targeted DMARDs+csDMARDs and placebo+csDMARDs, in inadequate responders to csDMARDs (csDMARD-IR) or tumour necrosis factor α inhibitors (TNFi-IR).MethodsSystematic literature review and network meta-analyses (NMA) conducted on 24 week efficacy and safety outcomes: Health Assessment Questionnaire Disability Index, modified total sharp score (mTSS, including 52 weeks), American College of Rheumatology (ACR) 20/50/70, European League Against Rheumatism Disease Activity Score 28-joint count erythrocyte sedimentation rate (DAS28)<2.6; serious infections/serious adverse events (including 52 weeks).Results53 trials were selected for NMA. csDMARD-IR: Sarilumab 200 mg+csDMARDs and 150 mg+csDMARDs were superior versus placebo+csDMARDs on all outcomes. Against most targeted DMARDs, sarilumab 200 mg showed no statistically significant differences, except superiority to baricitinib 2 mg, tofacitinib and certolizumab on 24 week mTSS. Sarilumab 150 mg was similar to all targeted DMARDs. TNFi-IR: Sarilumab 200 mg was similar to abatacept, golimumab, tocilizumab 4 mg and 8 mg/kg intravenously and rituximab on ACR20/50/70, superior to baricitinib 2 mg on ACR50 and DAS28<2.6 and to abatacept, golimumab, tocilizumab 4 mg/kg intravenously and rituximab on DAS28<2.6. Sarilumab 150 mg was similar to targeted DMARDs but superior to baricitinib 2 mg and rituximab on DAS28<2.6 and inferior to tocilizumab 8 mg on ACR20 and DAS28<2.6. Serious adverse events, including serious infections, appeared similar for sarilumab versus comparators.ConclusionsResults suggest that in csDMARD-IR and TNFi-IR (a smaller network), sarilumab+csDMARD had superior efficacy and similar safety versus placebo+csDMARDs and at least similar efficacy and safety versus other targeted DMARDs+csDMARDs.

scholarly journals Current Therapy of Rheumatoid Arthritis (part 2)

2018 ◽  
Vol 1 (2) ◽  
pp. 90
Author(s):  
Hendrata Erry Andisari
Keyword(s):  
Tumor Necrosis ◽  
Biological Agents ◽  
Current Therapy ◽  
Disease Modifying Antirheumatic Drugs ◽  
Antirheumatic Drugs ◽  
Conventional Dmards ◽  
Inflammatory Drugs ◽  
Disease Modifying ◽  
And Control ◽  
Necrosis Factor

<p><em>Therapy in RA has undergone many advances today and in line with knowledge of the pathogenesis of RA, the current therapeutic goal is to alter the journey and control the activity of RA disease. Several groups of drugs have been used in RA therapy including non-steroidal anti-inflammatory drugs (NSAIDs), conventional disease-modifying antirheumatic drugs (DMARDs) as well as biological agents (bDMARD), glucocorticoids and anti-pain medicines. In recent years, the development of biological agents that have specific targets for inflammatory mediators such as interleukin (IL) -1, IL-6 and Tumor Necrosis Factor (TNF) suggests a potent therapeutic effect on RA. In this article will be presented the latest biological agents as the latest therapy on RA.</em></p><p> </p><strong><em>Keyword</em></strong><em>s : conventional DMARDs, biological agents</em>

Spondyloarthropathies

2011 ◽  
Author(s):  
Sandeep Bawa ◽  
Paul Wordsworth ◽  
Inoshi Atukorala
Keyword(s):  
Positive Association ◽  
Joint Involvement ◽  
Hla B27 ◽  
Resonance Imaging ◽  
Disease Modifying Antirheumatic Drugs ◽  
Peripheral Arthritis ◽  
Antirheumatic Drugs ◽  
Skeletal Involvement ◽  
Inflammatory Drugs ◽  
Necrosis Factor

♦ Spondyloarthropathies are related conditions typically associated with axial skeletal involvement, absence of rheumatoid factor, familial clustering, and a variable positive association with HLA-B27♦ Ankylosing spondylitis is the prototype with sacroiliac joint involvement being a prerequisite for diagnosis♦ Diagnosis is frequently delayed for several years but the use of magnetic resonance imaging to detect sacroiliitis greatly facilitates the establishment of an early diagnosis♦ Psoriatic arthritis, reactive arthritis, and enteropathic arthritis have prominent peripheral joint involvement with variable degrees of spinal involvement♦ Non-steroidal anti-inflammatory drugs and physical therapy are the cornerstones of management but slow-acting disease-modifying antirheumatic drugs only have a role in peripheral arthritis♦ Anti-tumour necrosis factor biologic agents have revolutionized the treatment of the spondyloarthropathies.

scholarly journals Recent Therapeutics Policies of Arthritis Rheumatoid (part I)

2018 ◽  
Vol 1 (1) ◽  
pp. 12
Author(s):  
Hendrata Erry Andisari
Keyword(s):  
Tumor Necrosis Factor ◽  
Tumor Necrosis ◽  
Biological Agents ◽  
Disease Modifying Antirheumatic Drugs ◽  
Antirheumatic Drugs ◽  
Inflammatory Drugs ◽  
Disease Modifying ◽  
And Control ◽  
Necrosis Factor ◽  
Arthritis Rheumatoid

<p>Therapy in RA has undergone many advances today and in line with knowledge of the pathogenesis of RA, the current therapeutic goal is to alter the journey and control the activity of RA disease. Several groups of drugs have been used in RA therapy including non-steroidal anti-inflammatory drugs (NSAIDs), conventional disease-modifying antirheumatic drugs (DMARDs) as well as biological agents (bDMARD), glucocorticoids and anti-pain medicines. In recent years, the development of biological agents that have specific targets for inflammatory mediators such as interleukin (IL) -1, IL-6 and Tumor Necrosis Factor (TNF) suggests a potent therapeutic effect on RA. In this article will be presented the latest biological agents as the latest therapy on RA.</p>

Sign in / Sign up

Export Citation Format

Share Document